Wakefield Asset Management LLLP Makes New Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Wakefield Asset Management LLLP acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 1st quarter, HoldingsChannel reports. The fund acquired 14,163 shares of the specialty pharmaceutical company’s stock, valued at approximately $979,000.

Other institutional investors have also modified their holdings of the company. Pacer Advisors Inc. purchased a new position in ANI Pharmaceuticals in the 4th quarter valued at $41,000. AJOVista LLC acquired a new position in ANI Pharmaceuticals during the fourth quarter worth about $58,000. China Universal Asset Management Co. Ltd. grew its stake in ANI Pharmaceuticals by 361.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock valued at $131,000 after acquiring an additional 1,854 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $132,000. Finally, Clear Street Markets LLC purchased a new position in ANI Pharmaceuticals in the 4th quarter worth approximately $140,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Activity

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 5,000 shares of the company’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $63.58, for a total transaction of $317,900.00. Following the transaction, the chief financial officer now directly owns 161,968 shares in the company, valued at $10,297,925.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ANI Pharmaceuticals news, Director Renee P. Tannenbaum sold 2,000 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $63.87, for a total transaction of $127,740.00. Following the sale, the director now directly owns 18,211 shares in the company, valued at approximately $1,163,136.57. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Stephen P. Carey sold 5,000 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $63.58, for a total transaction of $317,900.00. Following the completion of the transaction, the chief financial officer now owns 161,968 shares of the company’s stock, valued at approximately $10,297,925.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 176,688 shares of company stock valued at $11,332,663. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Trading Up 1.0 %

ANI Pharmaceuticals stock traded up $0.62 during mid-day trading on Friday, hitting $61.44. The company’s stock had a trading volume of 129,342 shares, compared to its average volume of 181,688. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $1.29 billion, a PE ratio of 38.40 and a beta of 0.75. The stock’s fifty day moving average is $63.85 and its two-hundred day moving average is $62.08.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.16. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The firm had revenue of $137.43 million during the quarter, compared to the consensus estimate of $125.01 million. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.32 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ANIP shares. HC Wainwright upped their price target on ANI Pharmaceuticals from $87.00 to $94.00 and gave the company a “buy” rating in a research report on Wednesday, June 26th. Capital One Financial assumed coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective on the stock. Finally, Guggenheim reaffirmed a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $82.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.